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Early growth response 3 (Egr3) is an immediate early gene (IEG) that is regulated
downstream of a cascade of genes associated with risk for psychiatric disorders, and
dysfunction of Egr3 itself has been implicated in schizophrenia, bipolar disorder, and
depression. As an activity-dependent transcription factor, EGR3 is poised to regulate
the neuronal expression of target genes in response to environmental events. In the
current study, we sought to identify a downstream target of EGR3 with the goal of
further elucidating genes in this biological pathway relevant for psychiatric illness risk.
We used electroconvulsive stimulation (ECS) to induce high-level expression of IEGs in
the brain, and conducted expression microarray to identify genes differentially regulated
in the hippocampus of Egr3-deficient (−/−) mice compared to their wildtype (WT)
littermates. Our results replicated previous work showing that ECS induces high-level
expression of the brain-derived neurotrophic factor (Bdnf) in the hippocampus of WT
mice. However, we found that this induction is absent in Egr3−/− mice. Quantitative
real-time PCR (qRT-PCR) validated the microarray results (performed in males) and
replicated the findings in two separate cohorts of female mice. Follow-up studies of
activity-dependent Bdnf exons demonstrated that ECS-induced expression of both
exons IV and VI requires Egr3. In situ hybridization demonstrated high-level cellular
expression of Bdnf in the hippocampal dentate gyrus following ECS in WT, but not
Egr3−/−, mice. Bdnf promoter analysis revealed eight putative EGR3 binding sites in
the Bdnf promoter, suggesting a mechanism through which EGR3 may directly regulate
Bdnf gene expression. These findings do not appear to result from a defect in the
development of hippocampal neurons in Egr3−/− mice, as cell counts in tissue sections
stained with anti-NeuN antibodies, a neuron-specific marker, did not differ between
Egr3−/− and WT mice. In addition, Sholl analysis and counts of dendritic spines in
golgi-stained hippocampal sections revealed no difference in dendritic morphology or
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synaptic spine density in Egr3−/−, compared to WT, mice. These findings indicate that
Egr3 is required for ECS-induced expression of Bdnf in the hippocampus and suggest
that Bdnf may be a downstream gene in our previously identified biologically pathway
for psychiatric illness susceptibility.
Keywords: electroconvulsive therapy, immediate early genes, early growth response 3, brain-derived
neurotrophic factor, schizophrenia, psychosis treatment

Egr3-deficient (−/−) mice, indicating a requirement of Egr3 for
the normal function of this receptor (Gallitano-Mendel et al.,
2007). Hypofunction of NMDARs is one of leading hypotheses
for the etiology of schizophrenia (Javitt and Zukin, 1991; Olney
et al., 1999). Indeed, GRIN2A, the gene encoding the NMDAR
subunit GluN2A, is also located at one of the 108 schizophreniaassociated loci (Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014).
Based on these prior studies, we hypothesized that other
EGR3 target genes in the brain may be critical contributors to
neuropsychiatric disorders. Since neuronal expression of IEGs
is activity dependent, we used electroconvulsive seizure (ECS)
to maximally activate IEGs, and compared hippocampal gene
expression between mice lacking Egr3 and their wildtype (WT)
littermates. This experimental approach is particularly relevant
as ECS is an experimental model of electroconvulsive therapy
(ECT), which remains one of the most effective treatments for
severe mood and psychotic disorders. However, the mechanisms
underlying the efficacy of ECT remain elusive.
Here we show that induction of brain-derived neurotrophic
factor (Bdnf ), a critical neurotrophin involved in a wide range of
neurobiological functions, is significantly diminished or absent
in the hippocampus of mice lacking Egr3. Dysfunction of BDNF
has been implicated in numerous neuropsychiatric disorders
(Autry and Monteggia, 2012), including bipolar disorder and
schizophrenia (Durany et al., 2001). Like Egr3, Bdnf is also
induced in the hippocampus following ECS, and this expression
is associated with the effectiveness of antidepressant treatments in
reversing mood disorder-like phenotypes in rodents (Altar et al.,
2003; Adachi et al., 2008; Inta et al., 2013).

INTRODUCTION
The risk to develop neuropsychiatric illnesses is determined by
both genetic and environmental factors. We have hypothesized
that immediate early gene (IEG) transcription factors are
poised to modulate this dual contribution, as they are rapidly
activated in the brain in response to environmental stimuli
and, in turn, influence numerous neurobiological processes
that are dysfunctional in the brains of patients with mental
illness (Gallitano-Mendel et al., 2007, 2008; Huentelman et al.,
2015). These include memory formation and synaptic plasticity
(Gallitano-Mendel et al., 2007; Forbes et al., 2009), myelination
(Jessen and Mirsky, 2002; Davis et al., 2003; Dwork et al.,
2007), vascularization (Mechtcheriakova et al., 1999; Fahmy et al.,
2003; Hanson and Gottesman, 2005), and growth factor response
(Moises et al., 2002; Fahmy and Khachigian, 2007; Zakharyan
et al., 2014). Our prior work has focused on investigating the
functions of the IEG transcription factor early growth response
3 (Egr3), as it is regulated downstream of numerous proteins
that are associated with risk for neuropsychiatric disorders
(Gallitano-Mendel et al., 2007, 2008; Huentelman et al., 2015).
We have previously reported that Egr3-deficient (−/−) mice
have behavioral abnormalities consistent with animal models of
mental illness, including schizophrenia and bipolar disorder, that
are rescued by the antipsychotic medications used to treat these
disorders (Gallitano-Mendel et al., 2007, 2008). EGR3 has been
associated with risk for schizophrenia in Japanese, Korean, Han
Chinese, and US populations of European descent (Yamada et al.,
2007; Kim et al., 2010; Zhang et al., 2012; Huentelman et al., 2015)
and levels of EGR3 are reduced in the brains of schizophrenia
patients (Mexal et al., 2005; Yamada et al., 2007). Recently,
EGR3 was identified as a master regulator in a network of
genes differentially expressed in the postmortem brains of bipolar
disorder patients, compared with controls, in two independent
cohorts (Pfaffenseller et al., 2016). In addition, although EGR3
was not identified within one of the 108 loci found to be
associated with schizophrenia risk in the Psychiatric Genomics
Consortium genome-wide association study (GWAS), numerous
genes encoding proteins that regulate or are regulated by EGR3
do map to these schizophrenia-associated loci (Schizophrenia
Working Group of the Psychiatric Genomics Consortium, 2014;
Marballi and Gallitano, 2018).
The few confirmed downstream target genes of EGR3 have
also been implicated in neuropsychiatric disorders. These include
glutamic acid decarboxylase A4 (GABRA4; Roberts et al., 2005,
2006), and activity-regulated cytoskeleton associated protein
(Arc-Arg3.1; Li et al., 2005). In addition, our prior studies
identified a specific deficit in GluN2B-containing N-methyl
D -aspartate receptors (NMDARs) in the hippocampus of
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MATERIALS AND METHODS
Mice
Previously generated Egr3−/− mice (Tourtellotte and Milbrandt,
1998) were backcrossed to C57BL/6 mice for greater than
20 generations. Studies were conducted on homozygous adult
littermate progeny of heterozygote matings, and assigned as
“matched pairs” at the time of weaning. Matched pairs were
exposed to identical conditions for all studies. The term WT
refers to +/+ littermates of Egr3−/− mice generated from these
crossings. Male mice ages 6–12 months (n = 4) were utilized for
the microarray and follow-up quantitative real-time PCR (qRTPCR) study. Results were validated in two separate cohorts of
female Egr3 mice. The first cohort included older adult females,
ages 12–15 months, from the same C57BL/6 background (n = 4–5
per group). A second cohort of females, age 3.5–6 months
(n = 4–5 per group), had a mixed background resulting from
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crossing the above Egr3 C57BL/6 background mice to a GENSAT
reporter line in a mixed FVB/N and Swiss Webster background.
Since these animals contain a bacterial artificial chromosome
expressing EGFP, in addition to a mixed background, results were
analyzed separately from other groups.
Animals were housed on a 12 h light/dark schedule with ad
libitum access to food and water. All studies were performed in
accordance with the University of Arizona, Institutional Animal
Care and Use Committee (IACUC). This study was carried out
in accordance with the recommendations of IACUC guidelines,
IACUC. The protocol was approved by IACUC.

kit (Ambion, Waltham, MA, United States) according to the
manufacturer’s protocol, and quantified using the NanoDrop
ND-1000 spectrophotometer (Thermo Scientific, Waltham, MA,
United States).

Microarray Procedure and Analysis
Data analysis and quality control was initially performed using
Gene Pattern (Reich et al., 2006), with normalization using the
cubic spline method using the following settings (FDR < 0.05)
to determine significantly differentially expressed genes between
the WT and Egr3−/− groups 1 h following ECS. This was
the timepoint at which we expected the most enrichment
for EGR3 transcription factor targets, as Egr3 is maximally
induced by ECS (O’Donovan et al., 1998). A parallel analysis
using the Illumina Genome studio 2010 software was used to
determine differentially expressed genes by comparing the same
two groups using the following settings: background subtraction,
quantile normalization, p < 0.05 (T-test). Finally, a list of
common differentially expressed genes using both programs
was generated. Complete microarray results will be published
separately.

Electroconvulsive Stimulation and Tissue
Collection
To anesthetize the corneas of all animals, 0.5% proparacaine
hydrochloride ophthalmic solution (Akorn, Inc., Lake Forest,
IL, United States) was applied 5 min prior to electroconvulsive
stimulation (ECS). Male mice utilized in the microarray study
underwent ECS without general anesthesia. Female mice used
in the replication studies were anesthetized with isoflurane
(VetOne, Boise, ID, United States) administered in an enclosed
chamber at a flow rate of 0.5 mL/min in oxygen. Animals were
removed from the chamber after 2 min of full anesthetization,
transferred to room air to recover to a level of light anesthesia,
and then administered electrical stimulation of 260 A for 1 ms
duration and a pulsewidth of 0.3 mm, 1 ms. (Ugo Basile, Varese,
Italy) via orbital electrodes. Mice were observed to undergo
seizure, and were placed in their home cage to recover for one
hour prior to sacrifice. Control animals remained in their home
cages undisturbed.

qRT-PCR
For qRT-PCR studies, mRNA was reverse transcribed into cDNA
using a standard protocol (Maple et al., 2015), and used as
a template for qRT-PCR using FastStart SYBR Green Master
mix (Roche Applied Science, Indianapolis, IN, United States)
on a 7500 Fast Real-Time PCR machine (ThermoFisher
Scientific, Waltham, MA, United States). Each sample was
amplified in triplicate for both Bdnf and the housekeeping gene
phosphoglycerate kinase 1 (Pgk1). Pgk1 was selected for use as
a housekeeping gene as one of the least changed genes across
experimental groups in the microarray data and validated by
qRT-PCR in all cohorts.
General Bdnf primers were used to assess overall levels of total
Bdnf mRNA (Bdnf F, R) (Tallaksen-Greene et al., 2014). These
primers target a region common to all 12 transcripts of Bdnf
as revealed by NCBI primer blast analysis. For follow-up exonspecific studies, we focused on Bdnf exons IV and VI as removal
of these exons in vivo significantly reduces BDNF protein levels
in the mouse hippocampus (Maynard et al., 2016). In addition,
Bdnf transcripts containing exon IV and VI are highly induced
in vivo following ECS in the mouse frontal cortex (Martinowich
et al., 2011). Exon specific primers for Bdnf exons IV and VI
(Zheng and Wang, 2009) were used in our study. Fold changes in
gene expression and data were plotted using the 2−1CT method
(Le et al., 2013). Primer sequences used were as follows, Bdnf F:
TGG CCC TGC GGA GGC TAA GT; Bdnf R: AGG GTG CTT
CCG AGC CTT CCT; Pgk1 F: TGT TAG CGC AAG ATT CAG
CTA GTG; Pgk1 R: CAG ACA AAT CCT GAT GCA GTA AAG
AC; Bdnf exon IV F: CTC CGC CAT GCA ATT TCC AC; Bdnf
exon VI F: GTG ACA ACA ATG TGA CTC CAC; and Bdnf exon
IV/VI R: GCC TTC ATG CAA CCG AAG TA.

Tissue Collection and RNA Isolation
Animals were sacrificed via isoflurane overdose, followed by
decapitation. The brains were removed, rinsed in sterile icecold phosphate buffered saline (PBS), and hemisected along the
central sulcus into right and left hemispheres for further studies
to quantify both the expression of mRNA with qRT-PCR and in
situ hybridization, respectively.
Hippocampal tissue was dissected and immediately placed
in RNAlater (Ambion, Waltham, MA, United States). Tissue
was transferred to 1.5-mL Eppendorf tubes, immediately placed
on dry ice, and transferred to −80◦ C until further use. For
male cohort microarray and follow-up qRT-PCR, RNA was
isolated using TRIzol reagent (Life Technologies, Carlsbad,
CA, United States) followed by phenol/chloroform extraction,
chloroform extraction, and isopropanol precipitation, per the
manufacturer’s protocol. RNA was resuspended in RNAse-free
water and quantitated by spectrophotometry. RNA quality and
concentration was validated by Agilent Bioanalyzer 2100 prior to
microarray analysis and reverse transcription for qRT-PCR. An
aliquot of the RNA samples was sent to the Microarray Resource
Center, Yale/NIH Neuroscience Microarray Center (New Haven,
CT, United States) for analysis using an Illumina Mouse WG6
v3.0 expression beadchip microarray. For female cohorts, RNA
isolation was performed using TRI reagent (Sigma-Aldrich, St.
Louis, MO, United States) and MagMaxTM Total RNA isolation
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Prediction of EGR3 Binding Sites in Bdnf
Gene Regulatory Regions
Bioinformatic identification of putative EGR binding sites in
the promoter of the mouse Bdnf gene was carried out using
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the TFBIND1 (Tsunoda and Takagi, 1999) website that utilizes
the transcription factor database TRANSFAC R. 3.3. Briefly, the
nucleotide sequence 4000 bp upstream of the start ATG in the
mouse Bdnf gene was exported from the UCSC genome browser2
using genome assembly GRCm38/mm10 and used to query the
TFBIND site. This generated an output that showed all the
putative binding sites for the EGR3 TF.

paraformaldehyde (PFA). Brains were harvested and were postfixed in 4% PFA for 24 h, rinsed in Tris-buffered saline (TBS,
pH 7.4), transferred into 30% sucrose, and stored at 4◦ C until
saturated, rinsed, and stored in TBS at 4◦ C. Tissue was sectioned
coronally at a thickness of 20 µm on a sliding microtome and
stored until further processing in a cryopreservative solution.

Immunohistochemistry
Tissue was rinsed in TBS, 3x × 5 min. Endogenous peroxidase
was quenched with 1% H2 O2 × 10 min in a buffer/detergent
solution (0.4% Triton-X in TBS). The reaction was stopped
by rinsing the tissue 3x × 5 min in TBS. Tissue was blocked
with 4% normal goat serum (Sigma-Aldrich, St. Louis, MO,
United States) prepared in 0.4% Triton-X in TBS at room
temperature (RT) for 2 h. Polyclonal rabbit primary antibody
raised against neuronal nuclei, NeuN (1:1000, Millipore, Cat
#ABN78) was prepared in 4% normal goat serum in 0.4% TritonX in TBS and was incubated at RT for 1 h with a 24-h incubation
at 4◦ C. A secondary biotinylated antibody raised against rabbit
(1:1000, Vector Labs, #BA-1000) was prepared in 4% normal
goat serum in 0.4% TBS-TX and was incubated with the tissue
for 1 h at RT. Avidin–biotin complex (ABC; ThermoFisher
Scientific, Waltham, MA, United States) was prepared at a
concentration of 1:1000 in TBS. Tissue was incubated in ABC
for 1 h at RT. Detection of the antigen was performed with
3,30 -diaminobenzidine (DAB) kit (ImmPACT DAB Peroxidase
Substrate, Cat No. SK-4105, Vector Laboratories, Burlingame,
CA, United States). Tissue sections were imaged with a Zeiss
Imager M2 microscope using a 40x objective, photographed using
an Axiocam 506 camera, and tiled together using Zen 2012
software (Zeiss Microscopy, Oberkochen, Germany).
Neurons were counted from defined anatomical regions
of CA1 and CA3 pyramidal neurons, as well as both the
suprapyramidal (DGsp ) and infrapyramidal (DGip ) blades of the
DG. For each brain, neurons were counted from four sections
spanning a total rostral–caudal distance of 200 µm including, and
caudal to, coordinates: interaural, 1.74 mm; bregma, 2.06 mm
(Paxinos and Franklin, 2001). The number of neurons within
each analyzed region of the hippocampus was estimated using
Abercrombie’s (1946) correction.

Golgi-Cox Preparation
Tissue was treated using the Golgi-Cox method, as previously
described (Gibb and Kolb, 1998; Gallitano et al., 2016). Briefly,
10 animals (5 Egr3−/− and 5 WT) were decapitated under
isoflurane and the brains were rapidly extracted. The brains were
rinsed in 0.9% saline and immersed in Golgi-Cox solution for at
least 14 days followed by 30% sucrose for at least 3 days. The
solution was made in the laboratory from ingredients purchased
from Sigma-Aldrich (St. Louis, MO, United States). Brains were
then sectioned on a Vibratome at 200 µm and mounted on
gelatin-coated slides.

Golgi-Cox Imaging and Analysis
Ten fully impregnated cells were selected in each region, from
the hippocampal Cornu Ammonis (CA) regions CA1 and CA3,
and the dentate gyrus (DG) of each animal, and were imaged
in a z-stack throughout the thickness of the section using a
brightfield microscope equipped with a digital camera (AmScope,
Irvine, CA, United States). Using ImageJ (NIH) or Metamorph
(Molecular Devices) software, several measures of dendritic
arborization were obtained (Figure 3). The Sholl technique
(Sholl, 1953) involves overlaying the neuron with a series of
concentric circles (20 µm apart) and recording the number
of dendritic processes intersecting each circle to a maximal
distance of 380 µm. In addition, branching order was calculated
for all cells. The primary dendrites originating from the soma
are assigned a branch order of one, while dendritic processes
originating from that dendrite are second-order branches, and
each subsequent bifurcation is assigned a progressively higher
branch order (van Pelt et al., 1986). Dendritic spine density
and morphology were analyzed at 100x under oil immersion.
Dendritic spines were counted in a sample of two random
20-µm-long segments in several distinct regions of each cell
according to the classification of Lorente de No (1934). For CA1
and CA3, these regions were: the basal tuft (stratum oriens), the
mid-point of the apical tuft (near the distal edge of the stratum
radiatum), and the distal tip of the apical tuft (stratum lacunosum
moleculare). In the DG, dendritic spines were counted in the
inner molecular layer (IML), middle molecular layer (MML), and
outer molecular layer (OML) as defined by dividing the length of
the molecular layer into three equal parts.

In Situ Hybridization
Tissue Preparation
Tissue was flash frozen in −40◦ C methylbutane and was
sectioned coronally at 10 µm thickness with a cryostat (Leika,
Buffalo Grove, IL, United States), mounted on super-charged
slides and stored at −80◦ C. Tissue sections from matched
experimental pairs of animals were mounted on a single slide
to control for possible staining differences (Egr3−/− control,
Egr3−/− ECS, WT control, and WT ECS).

Immunohistochemistry

Probe Generation

Animals were sacrificed by isoflurane euthanasia and
were perfused with PBS followed by fixation with 4%

Mouse BDNF DNA plasmid (accession #X55573) was kindly
donated by Dr. Stanley Watson, University of Michigan, Ann
Arbor. The DNA sequence was validated by comparison to
Bdnf reference sequence using FinchTV software (Geospiza, Inc.,
Seattle, WA, United States). Sense and antisense strands were

1
2

http://tfbind.hgc.jp
http://genome.ucsc.edu/
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generated by in vitro transcription with the AMBION Maxiscript
T7 kit (Ambion, Waltham, MA, United States), labeled with
digoxigenin RNA labeling mix (Roche, Basel, Switzerland), and
purified with mini columns according to the manufacturer’s
protocol. (Roche, Basel, Switzerland).

and thus expressed at low levels in the absence of a stimulus, we
used ECS to maximally activate IEG expression in both Egr3−/−
and WT mice, and compared levels of induced genes to those at
baseline. We conducted an expression microarray to screen for
genes that were differentially expressed in response to seizure in
the hippocampus of male WT, compared to Egr3−/−, mice.
Results of the microarray showed 65 genes to be differentially
expressed between WT and Egr3−/− mice following ECS. Of
these, 40 genes were increased (greater than 1.5-fold), while
13 were decreased, in WT mice following ECS compared to
Egr3−/− mice following ECS. Twelve genes were minimally
changed across both groups (1–1.4-fold). Bdnf was the only
growth factor among these 65 putative EGR3-dependent, ECSinduced genes. Complete results of the microarray will be
published separately.
Bdnf was of particular interest to us, as it has been shown to
contribute to the therapeutic effects of antidepressant treatments,
including ECS, in rodent models (Altar et al., 2003; Adachi et al.,
2008; Inta et al., 2013). Results of the expression microarray
demonstrated that, in WT mice, ECS produced a 2.5-fold increase
in Bdnf mRNA levels, measured 1 h following seizure, compared
to baseline unstimulated controls. This induction is dependent
upon Egr3, as Egr3−/− mice did not show a change in Bdnf
mRNA expression following seizure (Figure 1A). A two-way
ANOVA revealed a significant interaction of genotype and
treatment [F (1,12) = 12.65, p = 0.004]. Post hoc analysis showed
that WT mice had significantly higher levels of Bdnf induction
after ECS compared to the untreated WT (p < 0.001) mice,
while Egr3−/− mice did not show a significant increase in Bdnf
expression following ECS compared to baseline. In addition,
there was a significant difference in Bdnf levels between WT and
Egr3−/− mice following ECS (p < 0.01).
To validate these findings, we performed qRT-PCR from the
RNA samples that were used for the expression microarray
(Figure 1B). ECS induced a greater than six-fold increase in Bdnf
expression in WT mice (compared to non-stimulated control),
while it failed to induce a significant increase in Bdnf expression
in the Egr3−/− mice. These results validate the microarray data.
A main effect of treatment was observed using two-way ANOVA
[F (1,12) = 9.393, p = 0.0098] and post hoc analysis demonstrated
that ECS-treated WT mice had significantly higher levels of Bdnf
after ECS compared to the untreated WT (p < 0.05). ECS did not
result in a significant change in Bdnf expression in Egr3−/− mice
(p = 0.8133).
To determine whether the requirement of Egr3 for activitydependent induction of Bdnf is sex specific, we conducted ECS
in female Egr3−/− and WT mice. Figure 1C shows that, as in
male mice, ECS induced a significant increase (3.8-fold) in Bdnf
mRNA in WT female mice, but did not result in a statistically
significant increase in Egr3−/− mice. Cohort 1 (Figure 1C)
showed a significant interaction of genotype and treatment
[F (1,14) = 20.52, p = 0.0005] and post hoc analysis revealed
significant elevations in Bdnf levels post ECS in the WT group
compared to WT controls (p < 0.0001) and Egr3−/− ECS-treated
mice (p < 0.0001), respectively.
To determine whether the effect was also seen in younger
animals, we used a second cohort of female mice. Figure 1D

In Situ Hybridization
Tissue was fixed in 4% PFA at 4◦ C for 5 min., followed by a
wash in 2x SSC for 2 min at RT. Tissue was acetylated in acetic
anhydride (0.625%) for 10 min at RT, rinsed in sterilized water,
and delipidized with a 1:1 mixture of acetone and methanol
for 5 min. Tissue was rinsed in 2x SSC for 5 min, before
application of the probe (300 ng) prepared in hybridization buffer
(Sigma, St. Louis, MO, United States). The probe was applied
directly to the mounted tissue (250 µL/slide) and was coverslipped (FisherBrand, Fisher Scientific). Tissue was hybridized
in a humid, sealed chamber with a mixture of 2x SSC and
formamide overnight at 56◦ C. Stringency washes were performed
on Day 2 to remove any non-specific binding (protocol available
on request). Endogenous peroxidase was quenched with 2%
hydrogen peroxide, and tissue was permeabilized with 1x SSCTween followed by rinsing in 0.1 M TBS (pH 7.4). The tissue
was blocked with a mixture of 0.5% TSA blocking buffer
(PerkinElmer, Waltham, MA, United States) and 5% normal
sheep serum prepared in 0.1 M TBS. Anti-digoxigenin (Roche,
Basel, Switzerland; 1:400 dilution in blocking buffer) was applied
to the slides at RT for 2 h. Slides were washed in 0.1 M TBSTween 4x × 15 min at RT and the antibody was detected through
alkaline phosphatase development, SIGMAFAST BCIP/NBT
tablets (Sigma, St. Louis, MO, United States). Slides were imaged
with bright-field microscopy (Axiovision, Zeiss, Oberkochen,
Germany) at a magnification of 40x.

Statistical Analysis
All statistical analyses for qRT-PCR and in situ data were carried
out using graphpad prism. In all cases, two-way analysis of
variance (ANOVA) was performed followed by Tukey’s post hoc
test, corrected for multiple comparisons, and significance was set
at p < 0.05. Golgi-Cox impregnated granule cells and pyramidal
cells were analyzed in independent ANOVAs. Sholl data were
analyzed by repeated-measures ANOVA, while branching order
and spine density measures used general factorial ANOVA, with
genotype and hippocampal region (i.e., either CA1, CA3a/b,
and CA3c or DGsp and DGip) as factors. The neuron density
(number of neurons per unit area) was compared between WT
and Egr3-/- brains using a 2 × 5 ANOVA with genotype and
hippocampal region (i.e., CA1, CA3a/b, CA3c, DGsp , and DGip )
as factors.

RESULTS
Activity-Dependent Hippocampal Bdnf
Expression Depends on Egr3
To identify genes regulated by Egr3 in the mouse hippocampus,
we compared the complement of genes expressed in Egr3−/−
mice to that of WT mice. Since Egr3 is an activity-dependent IEG,
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FIGURE 1 | Electroconvulsive seizure (ECS)-induced hippocampal Bdnf expression is Egr3-dependent. Expression microarray analysis (A), and validation using
qRT-PCR (B–D), of hippocampal Bdnf expression from WT, and Egr3–/–, mice at baseline (no ECS) and 1 h after ECS. Two-way ANOVAs showed significant
interaction of genotype and ECS treatment on Bdnf expression in (A) male microarray data (p = 0.004) and qRT-PCR data in (C) female cohort 1 (p = 0.0005) and
(D) female cohort 2 (p = 0.0003), and (B) significant effect of treatment in original male cohort (p = 0.0098; n = 4–5 animals/group; ∗ p < 0.05, ∗∗ p < 0.01,
∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 controlled for multiple comparisons).

et al., 2016). Since exons IV and VI are required for expression
of the remaining BDNF exons, we decided to evaluate levels
of transcripts containing these two critical exons in WT and
Egr3−/− mice following ECS compared with untreated controls.
Quantitative real-time PCR using exon specific primers
showed that WT mice demonstrated a 10-fold increase in
Bdnf exon IV expression, 1 h post-ECS that was absent in
Egr3−/− mice (Figure 2A). Two-way ANOVA revealed a
significant interaction of genotype and treatment [F (1,12) = 12.52,
p = 0.0041]. Post hoc analysis indicated that WT mice had
significantly higher levels of Bdnf exon IV mRNA induction
after ECS compared to the untreated WT (p < 0.001) mice.
Egr3−/− mice did not show a significant increase in Bdnf exon
IV expression following ECS compared to baseline, but showed
decreased Bdnf exon IV expression compared to WT mice
following ECS (p < 0.01). Similar results were seen in both
female cohorts. Female cohort 1 (Figure 2B) WT mice exhibited
a sevenfold induction in Bdnf exon IV post ECS compared
to baseline. Two-way ANOVA showed a significant interaction
of genotype and treatment [F (1,14) = 14.46, p = 0.0019]. Post
hoc analysis demonstrated that WT mice had a significantly
greater induction of Bdnf exon IV following ECS compared
to baseline (p < 0.0001) and compared to Egr3−/− mice post
ECS (p < 0.001). WT mice from the second female cohort
demonstrated a ninefold induction in Bdnf exon IV post ECS
compared to non-stimulated controls (Figure 2C). Two-way

shows a similar result to that seen in adult male, and older
female, C57BL/6 mice, that ECS produces a fourfold increase in
Bdnf expression in WT mice that is dependent upon Egr3. Twoway ANOVA demonstrated a significant interaction of genotype
and treatment [F (1,13) = 23.85, p = 0.0003]. Post hoc analysis
revealed significant elevations in Bdnf post ECS in the WT group
compared to WT controls (p < 0.0001) and to Egr3−/− ECStreated mice (p < 0.0001). No significant effect of ECS on Bdnf
induction was observed in Egr3−/− mice in either group. These
data suggest that Bdnf induction by ECS is dependent, at least in
part, on Egr3.

ECS-Induced Exon IV and Exon VI Bdnf
Expression Is Egr3 Dependent
Given that the Bdnf gene has multiple splice variants, we next
examined whether Egr3 is required for ECS-induced expression
of specific splice variants. This was of particular interest as
ECS induces specific exon variants in the mouse brain in vivo
(Martinowich et al., 2011). Martinowich et al. (2011) showed that
mRNAs containing exon IV and exon VI are highly upregulated
following ECS compared to untreated mice, and mice that lack
exon IV fail to show induction of six splice variants following
ECS in vivo (Martinowich et al., 2011). In addition, both exon
IV and exon VI containing mRNAs maximally contribute to
total BDNF protein levels in the mouse hippocampus (Maynard
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FIGURE 2 | Electroconvulsive seizure (ECS)-mediated hippocampal induction of Bdnf exon IV and VI requires Egr3. Exon IV (A–C) and VI (D–F) hippocampal Bdnf
expression determined using qRT PCR from WT, and Egr3–/–, mice at baseline (no ECS) and 1 h after ECS. Two-way ANOVAs showed significant interactions of
genotype and ECS treatment on Bdnf exon IV expression in (A) original male cohort data (p = 0.0041), (B) female cohort 1 (p = 0.0019), and (C) female cohort 2
(p = 0.0001). Two-way ANOVAs showed significant effect of treatment on Bdnf exon VI expression in original (D) male cohort (p = 0.0099), (E) female cohort 1
(p = 0.0064), and (F) female cohort 2 (p = 0.0237; n = 4–5 animals/group; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 controlled for multiple
comparisons).

detect expression of Bdnf mRNA in hippocampal tissue sections.
In situ hybridization histochemistry was performed on tissue
sections from female Egr3−/− and WT mice at baseline,
and 1-h post ECS. In WT mice, ECS resulted in a strong
induction of Bdnf mRNA in the DG of the hippocampus 1 h
after ECS (Figure 3C) compared with baseline, unstimulated
controls (Figure 3A). Expression of Bdnf in the hippocampus
of WT mice at baseline is found in sparsely distributed
individual cells in the DG as well as CA regions 2 and
3 (Figure 3A). One hour following ECS, high level Bdnf
expression is evident uniformly throughout the dorsal and
ventral blades of the DG (Figure 3C). There is no evident
increase in the individual cellular pattern of labeling in CA2
and CA3 (Figure 3C). In Egr3−/− mice ECS did not result
in increased expression of Bdnf (Figure 3D) compared to
baseline (Figure 3B), and neither condition demonstrated strong
labeling of Bdnf in the DG, or in CA1, CA2, or CA3 regions
(Figures 3B,D).

ANOVA revealed a significant interaction of genotype and
treatment [F (1,13) = 30.24, p = 0.0001]. Post hoc analysis revealed
WT mice showed a significant induction of Bdnf exon IV post
ECS compared to baseline (p < 0.0001) and Egr3−/− mice that
underwent ECS (p < 0.0001).
In comparison, Bdnf exon VI mRNA was induced 2.2-fold
in male WT mice following ECS compared to baseline that was
absent in Egr3−/− mice (Figure 2D). Two-way ANOVA showed
a significant effect of treatment [F (1,12) = 9.361, p = 0.0099] and
post hoc analysis revealed a significant induction of Bdnf exon
VI in WT mice that underwent ECS vs. non-stimulated WT mice
(p < 0.05). These data were replicated in both female cohorts.
WT mice showed a 2.24- (Figure 2E) and a 2.64-fold (Figure 2F)
induction post ECS compared to baseline, in the first and second
female cohorts, respectively, that was absent in Egr3−/− mice.
Two-way ANOVA revealed a significant effect of treatment in
both female cohorts; female cohort 1 [F (1,14) = 10.26, p = 0.0064]
and female cohort 2 [F (1,13) = 6.557, p = 0.0237]. Post hoc analysis
revealed that significant induction of Bdnf exon VI in WT mice
that underwent ECS compared to baseline (p < 0.05) in both
female cohorts, while this effect was not observed in Egr3−/−
mice.

EGR3 Binding Sites Are Present in Bdnf
Regulatory Regions
If Egr3 is required to directly regulate expression of Bdnf,
then EGR3 binding sites should be present in the promoter
of the Bdnf gene. The genomic sequence 4000 bp upstream
of the Bdnf transcription start site contains eight highprobability putative binding sites for EGR3 (Figure 4
and Table 1), with a cutoff value of 0.74 designated
by TFBIND that calculates transcription factor-specific

ECS-Induced Bdnf Expression in
Dentate Gyrus Requires Egr3
To identify the location of Bdnf expression in the hippocampus
following ECS, and to determine in which regions it is
dependent on EGR3, we conducted in situ hybridization to
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FIGURE 3 | Bdnf induction in the hippocampal dentate gyrus requires Egr3. Representative tissue sections demonstrating in situ hybridization labeling of Bdnf
mRNA expressing cells in the hippocampus of WT and Egr3–/– mice at baseline (A,B) and 1 h following ECS (C,D). (A) Bdnf is expressed sparsely in CA3, CA2,
and the DG of WT mice at baseline. (C) ECS induces high-level Bdnf expression in the DG, and increased expression in CA3, CA2, and CA1 of WT mice. (B) Bdnf
expression in Egr3–/– mice is limited to rare cells in the CA3 region of the hippocampus, with no clear expression above background in the DG, CA2, or CA1, at
baseline. (D) ECS produces little to no increase in Bdnf expression in the DG, CA3, CA2, and CA1 regions of Egr3–/– mice.

FIGURE 4 | Map of predicted EGR3 binding sites in Bdnf upstream region. EGR3 binding sites identified in Table 1 are indicated in red. Positions are shown relative
to exon 1 of the mouse Bdnf gene as identified in the NCBI Refseq database. Numbers under each binding site correspond to numbered rows in Table 1.

cutoffs using an algorithm (Tsunoda and Takagi, 1999).
These sites represent a potential mechanism by which
EGR3 could regulate expression of the Bdnf gene. Further
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studies will be necessary to determine whether EGR3 binds
to these sites in vivo, and whether this binding may be
functional.
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TABLE 1 | EGR3 binding sites identified in the Bdnf promoter using TFBIND.
ID∗1

Score∗2

Position∗3

Strand∗4

Consensus sequence∗5

Identified sequence∗6

V$EGR3_01

0.807500

1947

(−)

NTGCGTGGGCGK

CCTCCCACGTCA

V$EGR3_01

0.753542

2881

(−)

NTGCGTGGGCGK

ACTCGCACTCAT

V$EGR3_01

0.741042

3144

(−)

NTGCGTGGGCGK

CCGCATCCGCCT

V$EGR3_01

0.901667

3175

(−)

NTGCGTGGGCGK

ACGCCCGCGCAC

V$EGR3_01

0.748958

3179

(−)

NTGCGTGGGCGK

CCGCGCACACGC

V$EGR3_01

0.771042

3181

(−)

NTGCGTGGGCGK

GCGCACACGCGC

V$EGR3_01

0.805417

3187

(−)

NTGCGTGGGCGK

ACGCGCACACAC

V$EGR3_01

0.777083

3296

(−)

NTGCGTGGGCGK

CAGCCTGCGCAG

∗1 ID: transcription factor matrix ID (from TRANSFAC R.3.4). V: vertebrate. ∗2 Score: degree of similarity between input sequence and registered sequence for the
transcription factor binding sites at the position shown in the position column (ranging from 0 to 1, representing low–high degree of similarity). ∗3 Position: location of
putative EGR3 binding site in the 4000 nucleotides upstream of Bdnf transcription start site. ∗4 Strand: location of EGR3 consensus sequences on + vs. − strand of DNA.
∗5 Consensus sequence (fixed) of the transcription factor binding sites. K = G or T; N = any base pair. ∗6 Putative EGR3 binding sequence identified by TFBIND.

[F (1,16) = 20.52, p < 0.001], indicating that granule cells in the
DGsp are significantly larger and more complex than granule cells
from the DGip , consistent with previous observations (Gallitano
et al., 2016), although branching order was not significantly
different [F (1,16) = 3.15, p = 0.09]. No interaction between
genotype and region was observed (p > 0.05 in all cases).

Hippocampal Neuronal Numbers Are Not
Affected by Developmental Absence
of Egr3
Egr3−/− mice lack expression of the functional gene throughout
development and life. It is therefore possible that the absence of
induction of Bdnf in the hippocampus following ECS in these
animals may be a consequence of abnormal development, or
survival, of hippocampal neurons in the absence of Egr3. To
determine whether this may be the case, we conducted detailed
regional cell counts of anti-NeuN antibody immunolabeled
neurons in the hippocampus of matched pairs of adult Egr3−/−
and WT littermate mice. WT and Egr3-/- brains display a
comparable distribution and density of neurons (Figure 5). As
expected (van Strien et al., 2009), a significant difference was
observed on the basis of hippocampal region [F (4,50) = 9.13,
p < 0.001], with the DG showing the tightest cell packing
density, while the CA3 regions were the least densely packed.
However, there was no difference in the number of neurons
in any hippocampal regions between Egr3−/− and WT control
mice. No significant main effect of genotype [F (1,50) = 1.19,
p = 0.28] or interaction between genotype and hippocampal
region [F (4,50) = 0.10, p = 0.98] was observed.

Spine Density Is Not Affected by Loss of
Egr3
Consistent with the dendritic analysis, ANOVAs showed no
significant differences in spine density in any brain region
(Figure 6). In pyramidal cells, no significant difference on the
basis of genotype in the density of basal spines in stratum oriens
[F (1,24) = 0.35, p = 0.5588], in apical spines in stratum radiatum
proximal [F (1,24) = 0.64, p = 0.43] or distal [F (1,24) = 0.35,
p = 0.56] to the soma, nor in stratum lacunosum/moleculare
[F (1,24) = 1.31, p = 0.26]. Similarly, no significant differences
were observed on the basis of hippocampal region (i.e., CA1,
CA3a/b, and CA3c) basal spines in stratum oriens [F (2,24) = 0.92,
p = 0.41], in stratum radiatum proximal [F (2,24) = 0.42, p = 0.66]
or distal [F (2,24) = 0.27, p = 0.77] to the soma, nor in stratum
lacunosum/moleculare [F (2,24) = 0.5624, p = 0.5772]. Similarly,
no significant interactions were observed between region and
genotype (p > 0.05 in all cases).
In granule cells, there was no significant effect of genotype
on the density of spines in the IML [F (1,16) = 0.31, p = 0.58],
MML [F (1,16) = 0.14, p = 0.71], or OML [F (1,16) = 0.33,
p = 0.58]. Similarly, no significant differences in spine density
were observed on the basis of blade of the DG (i.e., DGsp vs.
DGip ) in IML [F (1,16) = 0.28, p = 0.64], MML [F (1,16) = 0.33,
p = 0.57], or OML [F (1,16) = 0.76, p = 0.30]. Similarly,
no significant interactions were observed between region and
genotype (p > 0.05 in all cases).

Dendritic Complexity Remains Normal in
Egr3−/− Mice
To further characterize how the absence of functional Egr3
may alter the structure of hippocampal neurons, we conducted
detailed analyses of cells impregnated with Golgi-Cox solution
in adult WT and Egr3−/− littermate mice (Figures 6A,B).
In pyramidal cells (Table 2), no significant differences were
observed in the Sholl analysis [F (1,24) = 2.71, p = 0.11] or
branching order [F (1,24) = 0.81, p = 0.38] on the basis of genotype.
Moreover, no significant main effect of region was observed
on Sholl analysis [F (2,24) = 1.32, p = 0.29], or branching order
[F (2,24) = 0.68, p = 0.51], and no interaction between genotype
and region was observed (p > 0.05 in all cases). Similarly,
granule cells (Table 3) showed no significant differences in
the Sholl analysis [F (1,16) = 0.11, p = 0.75) or branching
order [F (1,16) = 1.678, p = 0.21] on the basis of genotype.
A significant main effect of region was observed on Sholl analysis
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Egr3 is an IEG transcription factor that is induced in response
to environmental stimuli (Thompson et al., 2010; Maple et al.,
2015). We have hypothesized that dysfunction of Egr3 could
disrupt the brain’s normal neurobiological response to stress,

9

May 2018 | Volume 12 | Article 92

Meyers et al.

Hippocampal Bdnf Induction Requires Egr3

with risk for schizophrenia in Japanese, Korean, Han Chinese
populations, and populations of European Descent (Yamada
et al., 2007; Kim et al., 2010; Zhang et al., 2012; Huentelman
et al., 2015), and Egr3 expression is decreased in the brains
of patients with schizophrenia, compared with controls (Mexal
et al., 2005; Yamada et al., 2007). Bioinformatics approaches have
identified Egr3 as a central gene in a network of transcription
factors and microRNAs implicated in schizophrenia risk (Guo
et al., 2010), as well as a master regulator of genes differentially
expressed in the brains of bipolar disorder patients in two
independent cohorts (Pfaffenseller et al., 2016). Together, these
findings suggest that disruption of Egr3 activity, or function of
other proteins that act either upstream or downstream in the
EGR3 pathway, may mediate both the genetic and environmental
factors that contribute to risk for severe mental illnesses (Marballi
and Gallitano, 2018).
Since EGR3 functions as a transcription factor, we
hypothesized that the downstream target genes regulated
by EGR3 may also influence risk for psychotic disorders. IEGs,
including Egr3, are expressed at low levels at baseline. We
therefore conducted ECS to induce rapid, high-level, expression
of Egr3 (O’Donovan et al., 1998). We used a microarray
approach to compare genes expressed 1 h following ECS in the
hippocampus of WT, compared to Egr3−/−, mice to identify
EGR3-dependent target genes. This study revealed increased
expression of Bdnf, in the WT mice, but not in the Egr3−/− mice,
indicating that ECS-induced Bdnf expression requires Egr3.
BDNF is a neurotrophic factor that promotes growth and
differentiation of neurons and synapses (Barde et al., 1987;
Binder and Scharfman, 2004; Bennett and Lagopoulos, 2014). In
addition, BDNF has been found to play a role in the therapeutic
effectiveness of treatments for psychiatric illnesses. Animals
treated with antidepressant medications demonstrate increased
expression of Bdnf in the hippocampus (Bjorkholm and
Monteggia, 2016). Disruption of BDNF function is implicated
in the pathology underlying numerous psychiatric disorders,
ranging from schizophrenia and bipolar disorder to depression
(Grande et al., 2010; Lee and Kim, 2010; Autry and Monteggia,
2012). Reduction of hippocampal BDNF attenuates the effect of
antidepressants (Monteggia et al., 2004; Adachi et al., 2008), and
infusion of BDNF into the hippocampus reverses depression-like
behavior in rodents (Shirayama et al., 2002).
The mouse Bdnf gene consists of nine exons; eight of which
are in the 50 untranslated region of the gene (exons I–VIII) and
only one of which encodes protein (exon IX; Aid et al., 2007).
Different Bdnf splice variants are formed from a combination
of one of the 50 untranslated exons (I–VIII) with the common
protein-coding exon (exon IX; Liu et al., 2005; McDowell
et al., 2010). Two alternative polyadenylation signals result in
transcription termination and result in either the short (0.3 kB)
or long (2.9 kB) 30 UTR of Bdnf (Timmusk et al., 1993).
Prior studies have shown that activity-dependent transcription
of Bdnf can be mediated by calcium influx (Shieh and Ghosh,
1999; West et al., 2001; Aid et al., 2007; Hong et al., 2008; West,
2008). Calcium responsive elements, including cAMP-responsive
element-binding (CREB) protein (West et al., 2001), Carf (Tao
et al., 2002), calcium-dependent phosphorylation of the methyl

FIGURE 5 | Egr3 is not required for development of normal numbers of
hippocampal neurons. Sample montaged photomicrographs from the
hippocampus of anti-NeuN stained (A) WT and (B) Egr3–/– mice show no
obvious signs of changes in gross morphology (scale bar = 100 µm).
Consistent with this observation, (C) quantification of NeuN+ cells (n = 6
animals/genotype) demonstrated no significant differences in neuron density
in any hippocampal region between WT (black) and Egr3–/– (gray) mice.

resulting in increased risk to develop mental illnesses such as
schizophrenia and bipolar disorder (Gallitano-Mendel et al.,
2007, 2008; Williams et al., 2012; Huentelman et al., 2015;
Pfaffenseller et al., 2016; Marballi and Gallitano, 2018). In support
of this hypothesis, our prior work has shown that Egr3−/− mice
display behavioral abnormalities consistent with animal models
of psychotic disorders that can be reversed by administration of
medications used to treat these illnesses in humans (GallitanoMendel et al., 2007, 2008). In addition, Egr3 has been associated
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FIGURE 6 | Egr3 is not required for normal development of neuronal morphology. Samples of Golgi-Cox staining in (A) granule cells and (D) pyramidal cells shows
impregnation of both gross dendritic structure (scale bar = 20 µm) as well as spines (inset, scale bar = 10 µm). Quantitative data show no statistically significant
differences in either dendritic morphology or spine number between WT (black) and Egr3–/– (gray) mice in the (B) DGsp , (C) DGip , (E) CA1, (F) CA3a/b, or (G) CA3c
regions.

Frontiers in Behavioral Neuroscience | www.frontiersin.org

11

May 2018 | Volume 12 | Article 92

Frontiers in Behavioral Neuroscience | www.frontiersin.org

0.84 ± 0.27

24.51 ± 2.48

8+

Total

12

1 All

4.55 ± 0.45

5.63 ± 0.60

6.00 ± 0.53

5.09 ± 0.41

3.50 ± 0.41

1.99 ± 0.21

1.11 ± 0.10

0.69 ± 0.18

0.30 ± 0.06

0.11 ± 0.09

52.00 ± 9.93

140

160

180

200

220

240

260

280

300

320

Total

−
39.10 ± 19.02

44.95 ± 4.88

−

−

−

−1
−

1.28 ± 0.30

1.90 ± 0.52

2.08 ± 0.76

3.00 ± 1.15

3.88 ± 1.23

4.48 ± 1.00

5.08 ± 0.76

4.65 ± 0.66

4.98 ± 0.45

4.85 ± 0.38

3.63 ± 0.36

2.58 ± 0.68

1.70 ± 0.17

19.90 ± 3.68

0.50 ± 0.29

1.60 ± 0.92

1.70 ± 0.37

3.03 ± 0.45

2.23 ± 0.31

3.05 ± 0.84

3.28 ± 0.27

2.53 ± 0.42

Apical

0.50 ± 0.28

1.75 ± 0.98

2.75 ± 0.24

3.50 ± 0.24

4.50 ± 0.68

4.75 ± 1.98

4.25 ± 2.04

7.00 ± 3.79

6.00 ± 3.51

4.75 ± 1.72

5.00 ± 2.14

3.75 ± 0.60

1.50 ± 0.70

30.75 ± 4.90

0.25 ± 0.12

1.00 ± 0.47

2.50 ± 0.95

5.75 ± 1.08

7.00 ± 0.65

7.00 ± 0.74

4.75 ± 0.47

2.50 ± 0.47

Basal

Basal

26.30 ± 4.33

−

−

−

−

−

−

−

−

−

0.50 ± 0.29

0.85 ± 0.38

1.85 ± 0.95

4.63 ± 2.09

7.15 ± 1.36

8.78 ± 1.14

6.78 ± 0.56

16.48 ± 2.73

2.10 ± 0.07

4.40 ± 1.03

5.50 ± 1.03

5.90 ± 0.87

3.50 ± 0.87

3.35 ± 1.07

CA3a/b

42.60 ± 4.23

−

−

0.20 ± 0.12

0.40 ± 0.23

1.15 ± 0.38

1.35 ± 0.49

1.68 ± 0.53

2.50 ± 0.29

3.38 ± 0.36

3.48 ± 0.16

4.35 ± 0.49

6.45 ± 1.13

6.60 ± 0.35

5.28 ± 0.27

3.68 ± 0.62

1.73 ± 0.30

16.17 ± 3.65

−

0.27 ± 0.19

0.83 ± 0.59

2.37 ± 1.18

1.30 ± 0.78

2.53 ± 0.85

2.50 ± 0.84

1.77 ± 0.38

Apical

Basal

33.08 ± 4.93

−

−

−

−

−

−

−

−

−

1.35 ± 0.66

3.15 ± 0.78

5.45 ± 1.18

6.68 ± 1.20

10.43 ± 0.48

9.73 ± 0.30

6.93 ± 0.19

16.80 ± 2.77

1.80 ± 0.09

4.90 ± 0.10

5.30 ± 0.12

5.12 ± 0.78

4.38 ± 0.94

4.73 ± 0.85

CA3c

data are reported as mean ± SE. 2 Denotes that no observations could be made in this category.

4.22 ± 0.57

5.18 ± 0.32

100

120

5.19 ± 0.22

4.51 ± 0.26

60

80

3.50 ± 0.12

40

2.03 ± 0.14

1.57 ± 0.31

7

Scholl (µm) 20

6.02 ± 0.90

2.00 ± 0.49

5

6

5.89 ± 0.32

4.57 ± 0.39

3

4

1.30 ±

2.19 ± 0.55

1

2

Branching

Order

0.211

Apical

CA1

WT

TABLE 2 | Dendritic arborization in hippocampal cells of WT and Egr3−/− mice.
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1.13 ± 0.07

3.38 ± 0.65

3.96 ± 0.17

2.50 ± 0.14

2.13 ± 0.22

CA3a/b

Egr3−/−

42.15 ± 3.94

−

−

0.13 ± 0.06

0.50 ± 0.16

1.00 ± 0.26

1.50 ± 0.47

3.00 ± 0.94

4.13 ± 1.30

6.50 ± 1.90

6.75 ± 1.67

6.13 ± 1.47

5.34 ± 1.24

5.25 ± 1.43

3.25 ± 0.82

2.75 ± 0.72

1.38 ± 0.33

14.95 ± 1.99

−

0.51 ± 0.43

0.60 ± 0.12

2.00 ± 0.32

1.30 ± 0.16

3.20 ± 0.42

3.80 ± 1.04

2.01 ± 0.92

Apical

Basal

35.20 ± 4.58

−

−

−

−

−

−

−

−

−

0.19 ± 0.10

0.65 ± 0.09

2.75 ± 0.72

3.83 ± 0.91

5.25 ± 1.01

6.95 ± 0.84

5.78 ± 0.01

13.10 ± 0.64

0.29 ± 0.02

0.67 ± 0.19

2.83 ± 0.20

4.79 ± 0.22

3.46 ± 0.41

3.04 ± 0.17

CA3c
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TABLE 3 | Dendritic arborization in granule cells of WT and Egr3−/− mice.
WT

Egr3−/−

DGsp

DGip

DGsp

DGip

Branching

1

2.05 ± 0.171

2.04 ± 0.10

2.23 ± 0.12

2.08 ± 0.50

Order

2

4.13 ± 0.36

3.89 ± 0.28

4.65 ± 0.22

3.93 ± 0.47

3

5.08 ± 0.39

4.91 ± 0.21

5.55 ± 0.27

5.03 ± 0.68

4

3.63 ± 0.16

3.58 ± 0.77

4.38 ± 0.35

4.28 ± 1.02

5

1.225 ± 0.25

1.70 ± 0.39

1.50 ± 0.36

1.55 ± 1.15

6

0.45 ± 0.17

0.40 ± 0.21

0.63 ± 0.31

0.35 ± 0.37

7

0.45 ± 0.16

0.40 ± 0.21

0.53 ± 0.26

0.30 ± 0.37

8+

0.09 ± 0.04

0.01 ± 0.01

0.10 ± 0.06

0.05 ± 0.01

17.00 ± 0.61

16.91 ± 1.20

19.55 ± 1.36

17.55 ± 2.74

20

2.85 ± 0.28

3.13 ± 0.85

3.08 ± 0.26

3.27 ± 0.28

40

4.425 ± 0.20

4.48 ± 1.20

4.55 ± 0.38

4.39 ± 0.43

60

4.7 ± 0.16

5.83 ± 0.73

5.58 ± 0.49

5.53 ± 0.45

80

5.73 ± 0.20

6.05 ± 0.71

6.32 ± 0.38

5.94 ± 0.35

100

6.10 ± 0.16

6.33 ± 0.84

6.80 ± 0.39

6.02 ± 0.58

120

6.85 ± 0.19

6.63 ± 0.62

7.20 ± 0.31

6.52 ± 0.48

140

6.975 ± 0.21

6.50 ± 0.76

7.75 ± 0.49

6.55 ± 0.38

160

7.05 ± 0.26

6.30 ± 0.85

7.90 ± 0.40

6.50 ± 0.41

180

6.98 ± 0.28

5.65 ± 1.20

7.85 ± 0.46

5.95 ± 0.38

200

6.58 ± 0.27

5.08 ± 0.93

7.48 ± 0.50

5.45 ± 0.49

220

6.53 ± 0.23

4.48 ± 0.96

6.83 ± 0.50

5.40 ± 0.49

240

6.10 ± 0.18

3.48 ± 1.34

6.43 ± 0.44

4.36 ± 0.45

260

5.28 ± 0.25

2.50 ± 1.45

5.95 ± 0.31

3.55 ± 0.50

280

4.65 ± 0.33

1.70 ± 1.80

5.15 ± 0.28

2.29 ± 0.37

300

3.5 ± 0.27

0.95 ± 1.83

3.80 ± 0.23

1.37 ± 0.38

320

2.3 ± 0.20

0.40 ± 0.97

2.48 ± 0.29

0.64 ± 0.29

340

1.5 ± 0.44

0.25 ± 0.96

1.88 ± 0.55

0.48 ± 0.19

69.68 ± 10.45

97.01 ± 4.26

74.17 ± 5.41

Total
Scholl (µm)

Total
1 All

88.08 ± 2.15

data are reported as mean ± SE.

sites in the Bdnf promoter suggests the possibility that EGR3,
a transcription factor, may directly regulate expression of Bdnf.
However, since the current study did not confirm binding of
EGR3 to these sites in vivo, we are not able to determine this at
this time.
Exon IV in particular seems to be an important component
of activity-dependent Bdnf expression, as deletion of exon IV
impedes both ECS-induced, and sleep deprivation-mediated,
activation of several Bdnf transcripts in vivo (Martinowich
et al., 2011). Notably, both ECS and sleep deprivation activate
expression of Egr3 as well (Thompson et al., 2010; Maple et al.,
2015). Deletion of exon IV also causes impairments in spatial
memory reversal and fear memory extinction (Sakata et al., 2013),
deficits in GABAergic transmission in the cortex (Sakata et al.,
2009), and impairment of hippocampal synaptic plasticity (Sakata
et al., 2013) in vivo.
Another important activity-induced exon in the hippocampus
is exon VI (Chiaruttini et al., 2008). Both Bdnf exon IV
and VI contribute significantly to BDNF protein levels in the
hippocampus (Maynard et al., 2016). We found that both exon
IV and VI expression failed to show induction in Egr3−/− mice
following ECS compared to WT mice. Follow-up bioinformatic

CpG binding protein 2 (MeCP2), and the basic helix-loop-helix
upstream signaling factors (USFs; Chen et al., 2003), positively
regulate expression of Bdnf. In contrast, stressful environmental
stimuli, ischemia (Lindvall et al., 1992), and prenatal stress
(Boersma et al., 2014) lead to decreased expression levels of Bdnf
in the hippocampus.
One of the stimuli known to activate Bdnf is ECS. ECS is the
experimental equivalent of ECT, a treatment that has been in
use for more than 80 years, and that remains the most effective
treatment for severe mood disorders and psychotic disorders
with a mood component (Fink, 2001, 2014; Pagnin et al., 2004;
Rosenquist et al., 2014). ECT results in increased levels of BDNF
in peripheral blood in humans (Bocchio-Chiavetto et al., 2006).
Studies in rodents demonstrate that ECS induces high levels of
BDNF expression in the hippocampus (Altar et al., 2004). ECS
also induces expression of IEGs, including Egr3, as well as other
growth factors in addition to BDNF, and stimulates neurogenesis
and dendritic sprouting in the hippocampus (Duman and Vaidya,
1998; Malberg et al., 2000; Altar et al., 2004; Perera et al., 2007;
Kato, 2009; Youssef and McCall, 2014; Thomann et al., 2017).
Our findings show that hippocampal induction of Bdnf in
response to ECS requires Egr3. The presence of EGR3 binding
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analysis of the 4 kb proximal upstream region of Bdnf using
TFBind revealed eight high-probability EGR3 binding sites
(Table 1). Further studies will be important to confirm the
binding of EGR3 to these sites and confirm the specific conditions
and cell types in which they occur.
Psychotic disorders are characterized by cognitive
impairments (Goff et al., 2011). In animals, disrupting the
expression of BDNF results in deficits in learning, memory,
attention, executive function, and cognition (Sharma and
Antonova, 2003). Both Egr3 and BDNF play critical roles in
hippocampal synaptic plasticity, a process associated with
memory formation. Specifically, long-term depression, a form
of hippocampal plasticity that is facilitated by novelty and stress
exposure, requires Egr3, and is stimulated by the immature
form of BDNF, proBDNF (Kim et al., 1996; Woo et al., 2005;
Gallitano-Mendel et al., 2007; Yang et al., 2014; Bukalo et al.,
2016). The results of these, and many other studies, have led to
the hypothesis that BDNF may be a critical molecule in mediating
the therapeutic effects of psychiatric therapies, including ECT
(Bocchio-Chiavetto et al., 2006; Li et al., 2016).
One limitation of our study is that it employed mice that lack
Egr3 function throughout development and life. It is therefore
possible that the failure of ECS to induce Bdnf expression
in Egr3−/− mice could be explained by a developmental
deficit of the cells that normally express Bdnf. However, our
neuroanatomical studies demonstrated no regional differences in
neuronal counts in the DG or CA regions of the hippocampus
in Egr3−/− mice. Furthermore, no differences were found in the
spine density or branch order of pyramidal cells, or in the density
DG granule cells.
The absence of neuroanatomical deficits in Egr3−/− mice
is supported by our prior findings of normal activation of Arc
expression in DG granule cells following exposure to a novel
environment (Maple et al., 2017) and prior studies demonstrating
seizure-induced Arc expression in the hippocampus of Egr3−/−
mice (Li et al., 2005). However, this Arc expression dissipates over
several hours in Egr3−/− DG cells, compared to WT mice in
which Arc expression perdures for up to 8 h (Maple et al., 2017).
Thus, the hippocampal DG granule cells of Egr3−/− mice are
capable of expressing Arc in response to activity, but maintenance
of this expression requires Egr3. Our results indicate that the
numbers of DG cells remain consistent in the WT and Egr3−/−
mice, which suggests that the loss of Bdnf in these cells is due to
failed activation in the absence of Egr3.
Another limitation is that, although we show that Bdnf fails
to be induced following ECS in the Egr3−/− mice, and the
Bdnf promoter contains putative EGR3 binding sites, we cannot
rule out the possibility that an intermediary factor regulates
expression of Bdnf. Future studies will employ chromatin
immunoprecipitation (ChIP) to assess binding of EGR3 to the
Bdnf promoter in the hippocampus, as well as luciferase reporter
assays to demonstrate functionality of this binding in vitro.
The expression of IEGs is, by definition, independent of
protein synthesis. Since exons III and IV of the mouse BDNF
have been reported to have IEG activity (Lauterborn et al.,
1996; Binder and Scharfman, 2004; Sakata et al., 2009), this
indicates that Bdnf transcription should be dependent upon
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transcription factor proteins that are already present and poised
for activation. However, in our study, we demonstrate that Egr3,
an IEG transcription factor, mediates Bdnf mRNA expression
in response to ECS. Specifically, we found that Egr3 is required
for ECS-induced expression of Bdnf exons IV and VI, with a
larger effect on exon IV, in the hippocampus. Since our study
examined gene expression 1 h following ECS, it is possible
that Bdnf is initially activated in the brains of Egr3−/− mice,
but fails to be maintained in the absence of Egr3, as seen
with Arc expression in prior studies by our group and others
(Li et al., 2005; Maple et al., 2017). If this is the case, then
the induced IEG Bdnf transcripts would have to be degraded
within 1 h following ECS, a timeframe more rapid than that
of Arc.
Our studies identify the novel requirement of EGR3 for
hippocampal Bdnf expression in response to ECS. We further
show that EGR3 is required for seizure-induced expression of
Bdnf transcripts containing exons IV and VI. Notably, these
two isoforms are the greatest contributors to total BDNF protein
in the hippocampus (Maynard et al., 2016). These data suggest
the possibility that EGR3 may play a role in other forms of
activity-dependent Bdnf induction in the hippocampus, such
as that induced by high-frequency stimulation or exposure
to novelty. However, this will have to be tested in future
studies. This finding is of interest as both Egr3 and Bdnf
share several common features. These include essential roles
in hippocampal long-term depression (Gallitano-Mendel et al.,
2007; Novkovic et al., 2015; Bukalo et al., 2016) calciumsignaling-dependent activation (Mittelstadt and Ashwell, 1998;
Shieh et al., 1998), and genetic association with schizophrenia
(Gratacos et al., 2007; Yamada et al., 2007; Kim et al., 2010;
Ning et al., 2012; Zhang et al., 2012; Huentelman et al., 2015).
We have hypothesized that both Bdnf and Egr3 are crucial
components of a biological pathway implicated in mental illness
risk (Marballi and Gallitano, 2018). It will be interesting to
determine whether activity-dependent, EGR3-mediated BDNF
expression contributes to the therapeutic effects of ECT on the
mood and psychotic symptoms of patients with severe psychiatric
illnesses.
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